<![CDATA[
What Is the CD57 Test and Why Does It Matter in Lyme Disease?
For patients battling chronic Lyme disease, one of the most frustrating aspects of the illness is the difficulty of monitoring treatment progress. Standard Lyme serologies (ELISA and Western Blot) detect antibodies — but antibodies can remain positive for years after successful treatment, and they can be falsely negative in patients with active disease and suppressed immune systems. The CD57 test offers a different window into the immune system’s response to Borrelia infection.
CD57 is a surface marker found on a subset of natural killer (NK) cells — a type of innate immune cell responsible for identifying and destroying infected and abnormal cells. In the context of Lyme disease, CD57+ NK cells are uniquely suppressed, making this marker a valuable clinical tool for assessing disease activity and treatment response.
“The CD57 count is not a diagnostic test for Lyme disease,” clarifies Dr. Julian Douwes, Chief Medical Officer at St. George Hospital. “Rather, it is a monitoring tool that helps us gauge the immune system’s functional status and track a patient’s progress over the course of treatment. A rising CD57 count is one of the most encouraging signs we see in our Lyme patients.”
The Science Behind CD57+ NK Cells
Natural Killer Cells: Your Immune System’s First Responders
Natural killer cells are part of the innate immune system — the body’s rapid-response defense. Unlike T cells and B cells, which require time to develop targeted responses, NK cells can identify and eliminate infected cells immediately without prior sensitization. They are particularly important in defending against intracellular pathogens, viruses, and cancer cells.
NK cells express various surface markers that define their maturity, function, and activation status. CD57 is a marker of terminal differentiation — CD57+ NK cells represent the most mature, most cytotoxic subset of NK cells.
Why CD57+ NK Cells Drop in Chronic Lyme Disease
Research pioneered by Dr. Raphael Stricker demonstrated that patients with chronic Lyme disease exhibit a specific and significant decrease in CD57+ NK cells. This suppression appears to be relatively unique to Borrelia burgdorferi infection; it is not typically seen in other chronic infections, autoimmune diseases, or general immune suppression.
The mechanism is not fully understood, but several hypotheses have been proposed:
- Direct immune suppression by Borrelia — The spirochete’s ability to evade and suppress immune function may specifically target the CD57+ NK cell subset
- Chronic immune activation and exhaustion — Prolonged infection may drive CD57+ NK cells to apoptosis (programmed cell death)
- Biofilm-mediated immune evasion — Borrelia’s formation of biofilm communities may create an environment that chronically depletes this specific immune population
Stricker’s landmark study, published in Clinical and Diagnostic Laboratory Immunology, found that CD57+ NK cell levels were significantly lower in patients with chronic Lyme disease compared to healthy controls, and that levels correlated with disease severity and treatment response (Stricker & Winger, 2001).
How to Interpret CD57 Results
Reference Ranges
The absolute CD57+ NK cell count is typically reported as cells per microliter (cells/µL). While laboratory reference ranges vary, the following general guidelines are used clinically:
- Above 200 cells/µL — Normal range; unlikely active Lyme disease
- 100–200 cells/µL — Mildly suppressed; may indicate early, treated, or resolving Lyme infection
- 60–100 cells/µL — Moderately suppressed; consistent with active chronic Lyme disease
- Below 60 cells/µL — Severely suppressed; strongly suggestive of active, persistent Borrelia infection
What CD57 Can Tell You
- Disease activity — A low CD57 count in a symptomatic patient supports the clinical impression of active infection
- Treatment response — Rising CD57 levels during and after treatment indicate improving immune function and reduced Borrelia burden
- Relapse risk — A CD57 count that remains low or drops after discontinuing treatment may predict clinical relapse
- Treatment endpoint — A sustained CD57 count above 200, combined with symptom resolution, supports the decision to discontinue antimicrobial therapy
What CD57 Cannot Tell You
- It cannot diagnose Lyme disease by itself — other infections and conditions must be considered
- It does not identify which species or strain of Borrelia is involved
- It does not differentiate between active infection and post-treatment immune recovery (context matters)
- Normal CD57 does not definitively exclude Lyme disease
CD57 in the Context of Comprehensive Lyme Diagnostics
At St. George Hospital’s Lyme disease center, we never rely on a single test to assess Lyme disease. The CD57 test is most valuable when interpreted alongside:
Serological Testing
- ELISA (Enzyme-Linked Immunosorbent Assay) — Screening test for Borrelia antibodies; reasonable sensitivity but significant false-negative rate in chronic Lyme
- Western Blot (IgM and IgG) — Confirmatory test that identifies specific antibody bands; more specific than ELISA
- Elispot/LTT (Lymphocyte Transformation Test) — Measures cellular (T-cell) immune response to Borrelia antigens; can detect active infection even when antibody levels are equivocal
Co-infection Testing
Tick-borne co-infections — Babesia, Bartonella, Anaplasma, Ehrlichia, Rickettsia — frequently accompany Borrelia infection and can independently suppress immune function. Comprehensive co-infection testing is essential for accurate diagnosis and effective treatment.
Inflammatory and Immune Markers
- C3a and C4a complement markers (elevated in active Lyme and mold illness)
- CD3, CD4, CD8 lymphocyte subsets
- Immunoglobulin levels
- Inflammatory markers (hs-CRP, cytokine panels)
Functional Assessment
- Oxidative stress markers
- Mitochondrial function
- Heavy metal burden (metals can impair immune function and treatment response)
- Nutritional status (vitamin D, zinc, selenium — critical for NK cell function)
Learn more about our full range of diagnostic capabilities.
How We Use CD57 at St. George Hospital
St. George Hospital has treated Lyme disease patients since 1994, when our founder Prof. Dr. Friedrich Douwes first recognized the growing burden of tick-borne illness in Europe. Today, under the direction of Dr. Julian Douwes, we integrate the CD57 test into a comprehensive monitoring protocol:
- Baseline assessment — CD57 is measured at the initial diagnostic workup alongside full serologies, co-infection panels, and immune function markers
- Treatment monitoring — CD57 is retested every 4 to 8 weeks during active treatment to track immune recovery
- Treatment completion — A sustained CD57 above 200 cells/µL, combined with clinical improvement, supports the decision to transition from active treatment to maintenance
- Long-term surveillance — Periodic CD57 testing (every 3 to 6 months) after treatment completion helps detect early signs of relapse
Our treatment protocols combine advanced antimicrobial strategies with immune-supportive therapies including ozone therapy, therapeutic apheresis, hyperthermia, and targeted nutritional support — all designed to restore immune competence alongside pathogen elimination.
Limitations and Considerations
While the CD57 test is a valuable clinical tool, it is important to understand its limitations:
- Not universally accepted — Some conventional infectious disease specialists do not endorse CD57 testing for Lyme monitoring; it is more widely used in integrative and Lyme-literate medical practices
- Laboratory variability — Results can vary between laboratories depending on methodology (flow cytometry gating strategies); consistent use of the same laboratory is important for serial monitoring
- Other causes of low CD57 — While Lyme disease is the most studied cause, other conditions (certain cancers, severe immunosuppression) can also suppress CD57+ NK cells
- Research is ongoing — A 2021 review in Frontiers in Medicine noted that while clinical experience supports the utility of CD57 monitoring in Lyme disease, larger prospective studies are needed to standardize interpretation and establish evidence-based cutoff values (Bransfield, 2021)
Frequently Asked Questions
Can a normal CD57 count rule out Lyme disease?
No. While a significantly low CD57 count supports the clinical suspicion of chronic Lyme disease, a normal count does not exclude it. Some patients in the early stages of infection, or those with co-infections as the primary driver of symptoms, may have preserved CD57 levels. Diagnosis always requires the integration of clinical history, symptoms, and multiple laboratory markers.
How quickly does CD57 improve with treatment?
The rate of CD57 recovery varies considerably between patients. Some patients see meaningful improvements within 4 to 8 weeks of initiating effective treatment, while others require several months. Factors that influence recovery speed include duration of illness, presence of co-infections, heavy metal burden, nutritional status, and the specific treatment protocol employed. Slow CD57 recovery may prompt investigation of co-infections or immune-suppressive factors.
Is the CD57 test covered by insurance?
In Germany, the CD57 test is typically covered by private health insurance when ordered as part of a Lyme disease evaluation. Coverage under statutory insurance (Gesetzliche Krankenversicherung) is variable. For international patients, the cost of CD57 testing is modest and is included in our comprehensive Lyme diagnostic panels.
Can supplements improve CD57 levels without antibiotics?
While certain supplements — vitamin D, zinc, selenium, medicinal mushrooms (particularly beta-glucans) — can support NK cell function, supplementation alone is generally insufficient to normalize CD57 in the context of active Borrelia infection. We view nutritional and immune support as complementary to, not a substitute for, targeted antimicrobial and immune-modulatory treatment.
Get Tested at St. George Hospital
If you are living with chronic Lyme disease and want a thorough assessment of your immune status, CD57 testing is an important piece of the puzzle. At St. George Hospital, our Lyme-specialized physicians combine decades of experience with comprehensive diagnostics to develop individualized treatment plans.
Contact us to schedule your Lyme evaluation:
Phone: +49 (0)8061 398-0
Email: info@clinicum-stgeorg.de
Disclaimer: This article is for educational purposes only and does not replace professional medical advice. CD57 testing should be ordered and interpreted by physicians experienced in tick-borne disease management. Individual results and treatment responses vary.
]]>